Related Experiment Video
Updated: Jul 12, 2026

Working with Human Tissues for Translational Cancer Research
Published on: November 26, 2015
Physicians' understanding of consent requirements for phase I clinical trials in cognitively impaired or highly
Neil J Farber1, Brian M Aboff, Maria R DeJoseph
1Department of Medicine, Christiana Care Health System, 501 W. 14th St., Wilmington, DE 19899, USA. nfarber@christianacare.org
Abstract:
We investigated physicians' attitudes about entering patients who cannot give informed consent or who are of a vulnerable population into clinical trials. A survey instrument asked a nationwide sample of practicing physicians about whether ten hypothetical patients could be enrolled in a phase I clinical trials. The impact of demographic variables on the number of scenarios viewed as completely or somewhat acceptable was analyzed via student's T tests or analysis of variance (ANOVA) as applicable. All significant (p<0.01) variables were entered into a multiple logistic regression model. Eighty-four percent of respondents indicated that at least one case scenario was acceptable. A majority of those who conduct clinical trials (62%), who had training in the ethics of clinical research (78%), and who sit on institutional review boards (IRBs) (83%) approved of at least one case scenario. Physicians approved of the entry of some patients who cannot give informed consent or who are of a vulnerable population into clinical trials. More effective education on the guidelines involving clinical research should be available to practicing physicians, residents, and medical students. There should also be assurance that physicians who conduct clinical trials or who sit on IRBs have the requisite knowledge about the ethics of clinical research.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Nurses' Legal Responsibilities I
The legal responsibilities of a nurse regarding informed consent include the following:
Clinical Trials: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Dosing: Geriatric Patients
Pharmacodynamics in Geriatric Patients: Effects of Age

